MIRA Pharmaceuticals, Inc.
MIRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,306 | $1,573 | $2,351 | $684 |
| G&A Expenses | $4,713 | $6,500 | $2,992 | $770 |
| SG&A Expenses | $4,713 | $6,500 | $2,992 | $770 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $454 | $1,704 | $698 |
| Operating Expenses | $8,018 | $8,526 | $7,048 | $2,152 |
| Operating Income | -$8,018 | -$8,526 | -$7,048 | -$2,152 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $166 | -$3,456 | -$10 | -$24 |
| Pre-Tax Income | -$7,853 | -$11,982 | -$7,058 | -$2,177 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7,853 | -$11,982 | -$7,058 | -$2,177 |
| % Margin | – | – | – | – |
| EPS | -0.51 | -0.65 | -0.48 | -0.15 |
| % Growth | 21.5% | -35.4% | -220% | – |
| EPS Diluted | -0.51 | -0.65 | -0.48 | -0.15 |
| Weighted Avg Shares Out | 15,444 | 18,566 | 14,745 | 14,745 |
| Weighted Avg Shares Out Dil | 15,444 | 18,566 | 14,745 | 14,745 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $166 | $3,456 | $10 | $24 |
| Depreciation & Amortization | -$0 | $0 | $7,048 | $2,152 |
| EBITDA | -$8,018 | -$8,526 | $0 | $0 |
| % Margin | – | – | – | – |